Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Abstract Text:

Delbert G Robinson,Margaret G Woerner,Barbara Napolitano,Raman C Patel,Serge M Sevy,Handan Gunduz-Bruce,Jose M Soto-Perello,Alan Mendelowitz,Ali Khadivi,Rachel Miller,Joanne McCormack,Beth S Lorell,Martin L Lesser,Nina R Schooler,John M Kane,

OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders. METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day). RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%). Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria. Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine. Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone. Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone. CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable. Olanzapine may have an advantage for motor side effects. Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Publishing Authors By Initials

DG Robinson,MG Woerner,B Napolitano,RC Patel,SM Sevy,H Gunduz-Bruce,JM Soto-Perello,A Mendelowitz,A Khadivi,R Miller,J McCormack,BS Lorell,ML Lesser,NR Schooler,JM Kane,

For similar pathological conditions, signs and symptoms: signs and symptoms: body weight: body weight changes: weight gain research abstracts see: pathological conditions, signs and symptoms: signs and symptoms: body weight: body weight changes: weight gain research

PUBMED ID PMID:

MEDLINE DATE:

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The American journal of psychiatry

VOLUME: 163

Page Numbers: 2096-102

Journal Abbreviation:

ISSN: 0002-953X

DAY: 3

MONTH: Dec

YEAR: 2006

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370512

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Keywords Mesh Terms:

KEYWORDS: Weight Gain

MESH TERMS: drug effects

Chemical & Substance for Abstract: Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Information

Substance Name: olanzapine

Registry Number: 132539-06-1

Grant and Affiliation Information for Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.

AFFILIATION: Department of Psychiatry, The Zucker Hillside Hospital of the North Shore-Long Island Jewish Health System, Glen Oaks, NY 11004, USA. robinson@lij.edu

Country: United States

AGENCY: United States NCRR

GRANT: RR-018535

ACRONYM: RR

MEDLINETA: Am J Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes Related Publications

• 277.
• A modular, flexible training strategy to achieve competence in diagnostic and interventional musculoskeletal ultrasound in patients with hip osteoarthritis.
• A process to facilitate decision making in pediatric stem cell transplantation: the individualized care planning and coordination model.
• A role for N-cadherin in mesodermal morphogenesis during gastrulation.
• Advances and opportunities in assessing contaminant sensitivity of freshwater mussel (Unionidae) early life stages.
• Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.
• Demonstration of complex-conjugate-resolved harmonic Fourier-domain optical coherence tomography imaging of biological samples.
• Diploids heterozygous for a vma13Delta mutation in Saccharomyces cerevisiae highlight the importance of V-ATPase subunit balance in supporting vacuolar acidification and silencing cytosolic V1-ATPase activity.
• Editorial: schizophrenia international research society.
• Effects of body mass on nicotine-induced thermogenesis and catecholamine release in male smokers.
• Genomics and the future of pharmacotherapy in psychiatry.
• Geriatrics as a paradigm for good chronic care.
• Head injury - modern army combatives: 999: may 30 2:40 PM - 3:00 PM.
• Integer quantum Hall effect on a six-valley hydrogen-passivated silicon (111) surface.
• Laparoscopic Nissen fundoplication in an infant with situs inversus.
• Loss of vacuolar proton-translocating ATPase activity in yeast results in chronic oxidative stress.
• Metabolic risks and effects of atypical antipsychotic treatment.
• National survey of pediatric residency program directors and residents regarding education in palliative medicine and end-of-life care.
• Patient-reported outcomes in end-of-life research in pediatric oncology.
• RAVE is essential for the efficient assembly of the C subunit with the vacuolar H(+)-ATPase.
• Radiation medicine practice in the image-guided radiation therapy era: new roles and new opportunities.
• Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains.
• Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
• SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells.
• Scaffolds based on degradable alginate hydrogels and poly(lactide-co-glycolide) microspheres for stem cell culture.
• Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid.
• The contributions of strategy use to working memory span: a comparison of strategy assessment methods.
• The management of schizophrenia: safety, treatment, and continuity of care. Introduction.
• Treatment adherence and long-term outcomes.
• Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?